We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.33%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.83B
AUM Growth
-$147M
Cap. Flow
+$37.6M
Cap. Flow %
0.48%
Top 10 Hldgs %
76.26%
Holding
100
New
11
Increased
18
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$125M
2
INSM icon
Insmed
INSM
+$125M
3
ALKS icon
Alkermes
ALKS
+$103M
4
BCYC
Bicycle Therapeutics
BCYC
+$101M
5
ALMS
Alumis Inc
ALMS
+$20.8M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$308M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$55.5M
3
ROIV icon
Roivant Sciences
ROIV
+$50.6M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$38.2M
5
AKRO
Akero Therapeutics
AKRO
+$34.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRLD icon
26
Prelude Therapeutics
PRLD
$367M
$38.6M 0.49%
10,123,824
– –
IDYA icon
27
IDEAYA Biosciences
IDYA
$3.46B
$37.3M 0.48%
1,062,123
– –
CERS icon
28
Cerus
CERS
$575M
$34.3M 0.44%
19,477,339
– –
SERA icon
29
Sera Prognostics
SERA
$80.7M
$32.2M 0.41%
5,434,399
– –
KRYS icon
30
Krystal Biotech
KRYS
$10.7B
$31.2M 0.4%
169,934
– –
CELC icon
31
Celcuity
CELC
$4.01B
$30.7M 0.39%
1,874,978
+322,500
+21% +$5.4M
ROIV icon
32
Roivant Sciences
ROIV
$23.8B
$29.6M 0.38%
2,798,716
-4,615,118
-62% -$50.6M
IGMS
33
DELISTED
IGM Biosciences
IGMS
$28.1M 0.36%
4,090,316
+1,994
+0% +$17.1K
CERE
34
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$28M 0.36%
683,588
-916,412
-57% -$38.2M
AKRO
35
DELISTED
Akero Therapeutics
AKRO
$25.7M 0.33%
1,097,082
-1,616,123
-60% -$34.6M
DYN icon
36
Dyne Therapeutics
DYN
$4.15B
$23.7M 0.3%
672,096
+387,096
+136% +$11.2M
ALMS
37
Alumis Inc
ALMS
$3.37B
$20.8M 0.27%
+1,562,500
New +$20.8M
GLUE icon
38
Monte Rosa Therapeutics
GLUE
$1.85B
$18.4M 0.24%
4,916,095
– –
MRUS
39
DELISTED
Merus
MRUS
$17.8M 0.23%
+300,000
New +$14.5M
NGNE icon
40
Neurogene
NGNE
$656M
$16.6M 0.21%
456,015
– –
TCRX icon
41
TScan Therapeutics
TCRX
$48.8M
$16.3M 0.21%
2,784,792
– –
SANA icon
42
Sana Biotechnology
SANA
$865M
$13M 0.17%
2,380,949
– –
IMVT icon
43
Immunovant
IMVT
$7.93B
$12.3M 0.16%
464,718
+39,709
+9% +$1.13M
XNCR icon
44
Xencor
XNCR
$1.47B
$10.3M 0.13%
545,431
– –
NMRA icon
45
Neumora Therapeutics
NMRA
$306M
$10.2M 0.13%
1,034,600
+400,749
+63% +$4.15M
FATE icon
46
Fate Therapeutics
FATE
$272M
$9.83M 0.13%
2,997,772
+1,179,591
+65% +$5.16M
TSVT
47
DELISTED
2seventy bio
TSVT
$9.62M 0.12%
2,497,526
– –
BMEA icon
48
Biomea Fusion
BMEA
$88.9M
$9.49M 0.12%
2,108,949
– –
CLDX icon
49
Celldex Therapeutics
CLDX
$2.9B
$9.17M 0.12%
247,644
– –
TSHA icon
50
Taysha Gene Therapies
TSHA
$1.6B
$8.97M 0.11%
4,004,756
– –
1
2
3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Baker Bros. Advisors held 100 positions worth $7.83B, down 1.8% from $7.97B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors's Q2 2024 filing shows 11 new, 18 increased, 11 reduced and 5 closed positions. Its largest new stake was Summit Therapeutics: 23,222,222 shares worth $181M. The largest sale was Incyte, an estimated $308M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2024 buy was Summit Therapeutics: 23,222,222 shares worth $181M.
  • Baker Bros. Advisors added most to Insmed in Q2 2024, an estimated $125M increase.
  • Baker Bros. Advisors's biggest Q2 2024 reduction was Incyte, cutting an estimated $308M.
  • Baker Bros. Advisors fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $3.23M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $7.83B portfolio in Q2 2024.
  • Baker Bros. Advisors opened 11 new positions and closed 5 in Q2 2024.
  • Baker Bros. Advisors's portfolio value fell 1.8% quarter-over-quarter to $7.83B.

Based on Baker Bros. Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.